JP2021521248A - 嗅覚受容体活性を標的とすることによる免疫応答のモジュレート - Google Patents

嗅覚受容体活性を標的とすることによる免疫応答のモジュレート Download PDF

Info

Publication number
JP2021521248A
JP2021521248A JP2020558506A JP2020558506A JP2021521248A JP 2021521248 A JP2021521248 A JP 2021521248A JP 2020558506 A JP2020558506 A JP 2020558506A JP 2020558506 A JP2020558506 A JP 2020558506A JP 2021521248 A JP2021521248 A JP 2021521248A
Authority
JP
Japan
Prior art keywords
olfr
agent
expression
subject
deficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020558506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521248A5 (https=
JPWO2019204233A5 (https=
Inventor
クラウス レイ，
クラウス レイ，
マルコ オレッキオーニ，
マルコ オレッキオーニ，
Original Assignee
ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー
ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー, ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー filed Critical ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー
Publication of JP2021521248A publication Critical patent/JP2021521248A/ja
Publication of JP2021521248A5 publication Critical patent/JP2021521248A5/ja
Publication of JPWO2019204233A5 publication Critical patent/JPWO2019204233A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020558506A 2018-04-16 2019-04-15 嗅覚受容体活性を標的とすることによる免疫応答のモジュレート Pending JP2021521248A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658581P 2018-04-16 2018-04-16
US62/658,581 2018-04-16
PCT/US2019/027558 WO2019204233A1 (en) 2018-04-16 2019-04-15 Modulating immune response via targeting of olfactory receptor activity

Publications (3)

Publication Number Publication Date
JP2021521248A true JP2021521248A (ja) 2021-08-26
JP2021521248A5 JP2021521248A5 (https=) 2022-04-25
JPWO2019204233A5 JPWO2019204233A5 (https=) 2022-04-25

Family

ID=68240310

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020558506A Pending JP2021521248A (ja) 2018-04-16 2019-04-15 嗅覚受容体活性を標的とすることによる免疫応答のモジュレート

Country Status (4)

Country Link
US (1) US20210145768A1 (https=)
EP (1) EP3781173A4 (https=)
JP (1) JP2021521248A (https=)
WO (1) WO2019204233A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023084473A (ja) * 2021-12-07 2023-06-19 花王株式会社 フェノール化合物を原因とするにおいの抑制剤の評価及び／又は選択方法
WO2025187455A1 (ja) * 2024-03-08 2025-09-12 株式会社 資生堂 メラノサイトに対する紫外線の影響の抑制剤

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3827816A1 (en) * 2019-11-28 2021-06-02 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Prooxidative chain-transfer agents for use in the treatment of malignant tumour or infectious diseases
WO2021257905A2 (en) * 2020-06-17 2021-12-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Olfactory receptors for use as targets for antigen binding molecules to detect and treat cancer
WO2022128050A1 (en) * 2020-12-14 2022-06-23 Symrise Ag Medicament for fighting inflammation and pain
JP2022187352A (ja) * 2021-06-07 2022-12-19 エステー株式会社 嗅覚受容体の阻害剤、消臭剤、消臭方法
EP4241766A1 (en) * 2022-03-07 2023-09-13 Fondazione Per L'Istituto Oncologico Di Ricerca (IOR) Use of olfactory receptor or13a1 ligands in the treatment of lymphomas
IT202200010358A1 (it) * 2022-05-18 2023-11-18 Giuliani Spa Agonista del recettore olfattivo 2a4/7 per promuovere la crescita di capelli e migliorare l’aspetto estetico / olfactory receptor 2a4/7 agonist for promoting hair growth and improving aesthetic aspect
CN115840026B (zh) * 2023-02-13 2023-05-23 汉王科技股份有限公司 嗅觉受体在识别4-甲氧基苯甲醛中的用途和检测4-甲氧基苯甲醛的方法
KR20250044488A (ko) * 2023-09-21 2025-04-01 성균관대학교산학협력단 후각수용체 Olfr164를 제어하는 패혈증 치료용 조성물
CN118178367B (zh) * 2023-12-11 2024-09-13 南方医科大学 一种治疗胶质母细胞瘤的药物及其应用
US12290550B1 (en) 2023-12-27 2025-05-06 Olfactive Ai, Inc. Compositions and methods for treating endocrine diseases and disorders
US12102611B2 (en) * 2024-03-25 2024-10-01 Olfactive Biosolutions, LLC Compositions and methods for treating hypertension by modulating endocrine activity
CN120960185A (zh) * 2025-09-03 2025-11-18 江西农业大学 麝香酮在制备病毒抑制剂中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103976987A (zh) * 2014-06-04 2014-08-13 古天津 一种用于治疗动脉粥状硬化的组合物
JP2016535060A (ja) * 2013-08-27 2016-11-10 ドイチェス クレブスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓ Ｋｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ 細胞傷害性ｔ細胞応答の修飾物質

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006008074B4 (de) * 2006-02-22 2013-08-14 RUHR-UNIVERSITäT BOCHUM Behandlung von Krebs mit Geruchsrezeptor-Liganden
US20110196383A1 (en) 2009-05-05 2011-08-11 Atherolysis Medical, Inc Atherosclerotic Plaque Dissolution Composition
CA2993567C (en) 2010-07-21 2022-06-28 Sangamo Biosciences, Inc. Methods and compositions for modification of a t-cell receptor gene
KR101050436B1 (ko) * 2010-12-09 2011-07-19 연세대학교 산학협력단 대사질환과 연관된 후각수용체 유전자 및 그의 용도
JP5298258B1 (ja) * 2011-10-26 2013-09-25 パナソニック株式会社 マウス嗅覚受容体Ｏｌｆｒ１５を細胞膜に発現する方法
US11123292B2 (en) 2014-01-29 2021-09-21 Catherine S. Beaudin Use of biocompatible microdroplets for the treatment of atherosclerosis, heart disease and stroke
CN106668050A (zh) 2017-01-22 2017-05-17 新乡医学院 治疗动脉粥样硬化的药物组合物及应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535060A (ja) * 2013-08-27 2016-11-10 ドイチェス クレブスフォルシュングスツェントルムＤｅｕｔｓｃｈｅｓ Ｋｒｅｂｓｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ 細胞傷害性ｔ細胞応答の修飾物質
CN103976987A (zh) * 2014-06-04 2014-08-13 古天津 一种用于治疗动脉粥状硬化的组合物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BASIC RES. CARDIOL., vol. vol.112, issue 2, JPN6023019893, 2017, pages 1 - 20, ISSN: 0005214237 *
CELL, vol. vol.119, issue 5, JPN6023019892, 2004, pages 679 - 691, ISSN: 0005214238 *
EXP. DERMATOL., vol. vol.26, issue 7, JPN6023019895, 2017, pages 569 - 576, ISSN: 0005214235 *
PLOS ONE, vol. vol.12, issue 3, JPN6023019894, 2017, pages 0172491 - 1, ISSN: 0005214236 *
PLOS ONE, vol. vol.8, issue 11, JPN6023019896, 2013, pages 80148 - 1, ISSN: 0005214234 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023084473A (ja) * 2021-12-07 2023-06-19 花王株式会社 フェノール化合物を原因とするにおいの抑制剤の評価及び／又は選択方法
WO2025187455A1 (ja) * 2024-03-08 2025-09-12 株式会社 資生堂 メラノサイトに対する紫外線の影響の抑制剤

Also Published As

Publication number Publication date
EP3781173A4 (en) 2022-04-27
US20210145768A1 (en) 2021-05-20
WO2019204233A1 (en) 2019-10-24
EP3781173A1 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
JP2021521248A (ja) 嗅覚受容体活性を標的とすることによる免疫応答のモジュレート
JP6557827B2 (ja) 癌治療用医薬組成物
KR102871794B1 (ko) 네토시스 및 호중구 활성화를 치료하기 위한 방법
Stark et al. Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice
US11485787B2 (en) Agents that modulate RGMb-neogenin-BMP signaling and methods of use thereof
JP2022521454A (ja) 加齢関連炎症および障害を治療する、予防するまたは逆転させるための組成物および方法
JP2008523083A (ja) 炎症性疾患および免疫調節不全疾患、感染性疾患、病的血管新生およびがんの免疫療法および検出のための方法および組成物
JP2006508056A (ja) 心臓血管疾患を治療するための組成物および方法
CN114207117A (zh) 用于调节巨噬细胞活性的方法
JP6941565B2 (ja) がん転移を処置または防止するのに有用な化合物および組成物、ならびにこれらの使用法
JP2021011493A (ja) ＭＡｄＣＡＭアンタゴニストの投与レジメン
EP3986426A1 (en) Targeting alpha3beta1 integrin for treatment of cancer and other diseases
EP4326903A1 (en) Methods and compositions for treating cell senescence accumulation related disease
JP2024508611A (ja) 方法
JP7784120B2 (ja) 幹細胞遊走剤を使用した糖尿病治療
US20230391868A1 (en) Compositions for and methods of treating cancer
IL296755A (en) Monoclonal antibodies targeting hsp70 and their therapeutic uses
KR20230152099A (ko) 당뇨병 및 합병증의 신규 치료, 진단 및 검출을 위한 방법 및 제제
JP2024082527A (ja) 心不全の治療及び／又は予防用医薬組成物
JP7710224B2 (ja) 好中球抑制剤、及びクローン性造血の予防又は治療用医薬組成物
US20250297310A1 (en) Hematopoietic loss of y chromosome leads to cardiac fibrosis and dysfunction and is associated with death due to heart failure
US20250032405A1 (en) Hydrogel formulations, vaccines, and methods of use thereof
JP7458049B2 (ja) 自己免疫疾患治療剤
JP7599716B2 (ja) がんおよび他の疾患の診断および処置のための病原性細胞外マトリックスの同定および標的化
US20210322508A1 (en) Peptides and compositions for targeted treatment and imaging

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230517

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231207